- BriaCell (BCT) to present clinical and survival data in advanced metastatic breast cancer through four different posters
- The annual meeting is unfolding from April 14 to 19, 2023
- The posters will provide new insights and updates on previously-disclosed patient data and highlight late-breaking discoveries
- Copies of the posters will be available on the Briacell website under the “scientific publications” section
- The conference hopes to be an exciting event with presentations and discussions centred on cancer treatment, research, and innovation
- BriaCell Therapeutics (BCT) is down 3.11 per cent, trading at C$9.35 at 9:41 am EST
Clinical-stage biotechnology company BriaCell Therapeutics (BCT) will present four posters at the 2023 American Association for Cancer Research (AACR).
The annual meeting is unfolding from April 14 to 19, 2023, at Orange County Convention Center, Orlando, Florida.
The posters will provide new insights and updates on previously-disclosed patient data and highlight late-breaking discoveries.
Poster details
Led by a team from Creatv MicroTech, a diagnostic oncology company, the first two posters from BriCell will present research on the treatment of metastatic breast cancer.
Poster one:
“Whole cell antigen-presenting immune stimulating cells (Bria-IMT) for treating metastatic breast cancer.” It will be presented in Phase II Clinical Trials 1 session on Monday, April 17, from 1:30 PM to 5:00 PM.
Poster two:
“Engineering semi-allogeneic whole cancer vaccines with enhanced immunogenicity for the treatment of advanced solid tumours,” will be presented in the Immunology session titled “Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies” on Sunday, April 16, from 1:30 PM to 5:00 PM, at Poster Section 24.
Poster three:
“Tumor macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death,” will be presented in the Clinical Research Excluding Trials session titled “Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2” on Monday, April 17, from 9:00 AM to 12:30 PM, at Poster Section 44.
Poster four:
“Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer,” will be presented in the Molecular/Cellular Biology and Genetics session titled “Targeting Replication Stress and the Immune Microenvironment” on Sunday, April 16, from 1:30 PM to 5:00 PM, at Poster Section 11.
Copies of the posters will be available on the Briacell website under the “scientific publications” section.
The conference hopes to be an exciting event with presentations and discussions centred on cancer treatment, research, and innovation.
The posters presented by the Creatv MicroTech team will provide valuable insights into treating metastatic breast cancer, which remains a significant challenge in cancer research. The presentations will also offer an opportunity to learn about potential breakthroughs and innovations in cancer treatment and diagnosis.
BriaCell
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective cancer management approaches.
BriaCell Therapeutics (BCT) is down 3.11 per cent, trading at C$9.35 at 9:41 am EST.
